Loading...
•
Sep 30, 2020
Halozyme Q3 2020 Earnings Report
Reported a strong third quarter driven by royalty revenue growth and partner clinical trial progress.
Key Takeaways
Halozyme Therapeutics, Inc. reported third quarter 2020 financial results with revenue of $65.3 million and EPS of $0.25. The company is raising its full year 2020 financial guidance due to improved outlook for royalties and greater visibility on anticipated milestone revenues.
Revenue for the third quarter was $65.3 million, compared to $46.2 million for the third quarter of 2019.
Net income for the third quarter was $36.2 million, or $0.25 per share, compared to a net loss in the third quarter of 2019 of $25.0 million, or $0.17 per share.
The year-over-year increase was primarily driven by $32.0 million in collaboration revenue from Roche and argenx in the current period.
The company is raising full year 2020 financial guidance and now expects revenues of $250 million to $260 million and earnings per share on a GAAP basis of $0.80 to $0.85.
Halozyme
Halozyme
Halozyme Revenue by Segment
Revenue by Segment
Royalties Revenue
CapyFin.comUnder Collaborative Agreements Revenue
CapyFin.com Forward Guidance
The Company is raising full year 2020 financial guidance and now expects revenues of $250 million to $260 million and earnings per share on a GAAP basis of $0.80 to $0.85.
Positive Outlook
- Revenues of $250 million to $260 million
- Represents growth of 28 to 33% over prior year revenues
- Earnings per share on a GAAP basis of $0.80 to $0.85
- Increased from prior revenue guidance of $230 million to $245 million
- Increased from prior EPS guidance of $0.60 to $0.75
Revenue & Expenses
Visualization of income flow from segment revenue to net income